Abstract:Despite the efficacy and safety of the COVID-19 vaccine in the general population, for solid organ transplants, there is a theoretical concern regarding vaccination-triggered immunologic complications. In fact, several rejection episodes have been reported after mRNA COVID-19 vaccination.1,2 Contrary to mRNA vaccines that synthesize specific antigens to generate neutralizing antibody, whole-virus inactivated vaccines can activate the immunologic system more extensively as it used entire viral capsid. Additionally, new-onset and relapsed kidney pathological changes have been reported following COVID-19 vaccination in the general population, including minimal change disease, IgA nephrology, and membranous nephropathy.3,4 Thus, we conducted a prospective study in kidney transplants (KTs) to evaluate the safety of whole-virus inactivated COVID-19 vaccine, especially renal graft complications. This study has been registered in Clinical Trials.gov (NCT04969614). Between September 1, 2021, and January 31, 2022, 290 kidney recipients received inactivated whole-virus COVID-19 vaccine (Table S1, SDC, https://links.lww.com/TP/C546), including BBIBP-CorV (Vero cell) and Coronavac (Vero cell). The median age was 41 y with 2 adolescents, and the majority were male. 278 received 2 doses of inactivated COVID-19 vaccine and 12 received 1 dose only. Among 290 patients, 56.9% received living-donor KT, 39.3% received antithymocyte immunoglobulin as the induction therapy and 97.6% received tacrolimus plus mycophenolic acid and steroids as the maintenance therapy. The median duration from transplantation to vaccination was 38 mo. During the last year, 5 patients received high-dose steroid pulse therapy, 2 received antithymocyte immunoglobulin, and 3 received rituximab because of rejection events. The median follow-up was 4.2 mo after vaccination. After vaccination, 11% patients experienced a serum creatinine increment >10% and 0.7% had an increment >30% (Table 1). Seven patients (4.0%) had new-onset proteinuria after vaccination. Eight patients were diagnosed with acute rejection (AR) clinically (2.8%) with 4 biopsy-confirmed AR (1.4%, 2 antibody-mediated, 1 T-cell mediated, and 1 mixed) in a median follow-up of 34 d after vaccination. Additionally, 1 patient developed multiple myeloma after vaccination, confirmed by bone marrow and kidney biopsy, and experienced graft failure in 3 mo. No death was observed after vaccination. No severe local symptoms were observed, whereas 2 had severe fever, 2 severe chills, 6 severe fatigue, 3 severe headache, 2 severe myalgias, and 2 had severe diarrhea (Table S2, SDC, https://links.lww.com/TP/C546). TABLE 1. - Renal complications of 290 kidney transplant recipients after receiving inactivated COVID-19 vaccine Renal complications No. Events (proportion) Prevaccination eGFR, mL/min/1.73m2 282 68.4 (±19.3)/67.2 (14.2–134.7) Prevaccination creatinine, µmol/L 290 115 (±33.7)/110 (49–321) eGFR within 1–2 mo after vaccination, mL/min/1.73m2 267 68 (±18.9)/67.6 (8.9–128.8) Creatinine within 1–2 mo after vaccination, µmol/L 267 115 (±32.6)/110 (57–579) <10% increase 235 (89%) 10%–20% increase 25 (9.4%) 20%–30% increase 5 (1.9%) >30% increase 2 (0.7%) New-onset of proteinuria 174 No 167 (96.0%) Yes 7 (4.0%) Acute rejection 290 No 278 (95.8%) Yes 8 (2.8%) Biopsy-confirmed acute rejection 4 (1.4%) Graft loss 290 No 289 (99.6%) Yes 1 (0.4%) Patient death 290 No 290 (100%) Yes 0 (0%) eGFR, estimated glomerular filtration rate. Boyarsky et al reported that 1 of 176 experienced AR after receiving 2 doses of mRNA vaccines.5 Vaiciuniene et al reported 6 biopsy-confirmed ARs in 167 fully vaccinated KT recipients with mRNA vaccine in 9 mo follow-up.2 Our results provided the safety profile of the whole-virus inactivated COVID-19 vaccine in KTs, suggesting that more intensive monitoring of graft function after vaccination was necessary. Notably, due to lack of matched control group and ascertainment bias, it remains unclear whether there is casual association between renal complications and vaccination. Also, the role of immunosuppression modifications remains unclear. Well-designed prospective studies are still wanted to confirm this association.

Augmented Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 after Breakthrough Infection in Kidney Transplant Recipients Who Received 3 Doses of Coronavirus Disease 2019 Vaccine.

COVID-19 Breakthrough Infections in Vaccinated Kidney Transplant Recipients

Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study

A Third COVID-19 Vaccine Dose in Kidney Transplant Recipients Induces Antibody Response to Vaccine and Omicron Variants but Shows Limited Ig Subclass Switching

Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients

Antibody Response after 3-Dose Booster against SARS-CoV-2 mRNA Vaccine in Kidney Transplant Recipients

Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients

Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients

Relationship Between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients: The CONTRAST Cohort

Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre

Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent need

Serological responses and clinical outcomes following a three‐dose primary COVID‐19 vaccine schedule in kidney transplant recipients and people on dialysis

Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients

Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients

MO186: Third COVID-19 Vaccine Dose Maximizes Antibody Titer in Kidney Transplant Recipients

Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients

Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis

Renal Complications in Kidney Transplant Recipients after Whole-virus Inactivated COVID-19 Vaccination

Predictors of Specific Cellular Immunity Response in Kidney Transplant Recipients after Administration of SARS-CoV-2 Inactivated Vaccine

Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients

SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients